SCHEMBL3499284

SCHEMBL3499284

O=C(O)C1=Cc2cc(-c3ccc(Cl)cc3)ccc2S(=O)(=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALAD P13716 1/20 0.35
NOTUM Q6P988 1/20 0.35
POLB P06746 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
CTRC Q99895 2/20 0.33
CDH1 P12830 1/20 0.33
CTNNB1 P35222 1/20 0.33
TCF7L2 Q9NQB0 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
SRD5A1 P18405 2/20 0.32
SRD5A2 P31213 2/20 0.32
CNR1 P21554 1/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
GALR1 P47211 1/20 0.32
ALOX5 P09917 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7972704 0.88 KMO (0.40) POLBKMOCA12
SCHEMBL7974920 0.88 BCL2L1 (0.39) PTGDR2GALR1CA12ALPL
SCHEMBL7929501 0.87 MCL1 (0.39) PTGDR2RXRARXRBGALR1CA12
SCHEMBL7929550 0.86 RXRA (0.37) RXRARXRBCYP2C9VEGFA
SCHEMBL7969353 0.85 SLC6A3 (0.40) POLBCA12
SCHEMBL7970423 0.85 HAO1 (0.35)
SCHEMBL7931034 0.84 MAPT (0.41) RXRAERCC5FEN1CA12ALPL
SCHEMBL7972312 0.84 CCR5 (0.38) PTGDR2RXRARXRBGALR1CA12
SCHEMBL7931169 0.84 CA12 (0.39) PTGDR2RXRARXRBSRD5A2CA12
SCHEMBL7929509 0.82 KDM4E (0.37) POLBCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
US-6235771-B1 AIDS THERPAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 ALAD 4797/4885NOTUM 4060/4885POLB 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.